Epigenetic characterization and therapeutic targeting of cancers harboring dysfunctional CTCF.

CTCF 功能失调的癌症的表观遗传学特征和治疗靶向。

• 批准号: 379880
• 负责人: Witcher Michael
• 金额: $ 52.94万
• 依托单位: Lady Davis Institute for Medical Research (Mtl)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-03-01 至 2023-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=379880&lang=en
• 关键词: Ctcf; Epiegentics; Oncogenes; Therapeutics; Transcription; Tumor Suppressors

Tumor suppressor proteins act to limit the proliferation and survival of cells, thereby preventing cancer and its spread to throughout the body (known as metastasis. CTCF is a protein whose normal function is commonly disrupted in breast cancer and recent

肿瘤抑制蛋白的作用是限制细胞的增殖和存活，从而防止癌症及其扩散到全身（称为转移）。CTCF 是一种蛋白质，其正常功能通常在乳腺癌和近年来的癌症中被破坏。